Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

RNA sequencing may provide non-invasive endometriosis diagnoses for the first time, says GlobalData

Recently published findings from researchers at the Feinstein Institute in Manhasset, New York, supporting the use of single-cell RNA sequencing in diagnosing endometriosis could help provide faster diagnoses and earlier commencement of treatment, thereby cutting expenses for patients who often seek help from several different healthcare professionals before official diagnosis, says GlobalData, a leading data […]
Read more

Japan homegrown COVID-19 mRNA vaccine needs superior safety and efficacy data for success, says GlobalData

Following the unprecedented success of mRNA COVID-19 vaccines, pharma companies are working towards further developing the technology to capitalize on the tremendous growth opportunities. Recently, Daiichi Sankyo initiated Phase III trials of its COVID-19 vaccine, DS-5670, in healthy unvaccinated adults. Although it is a promising homegrown mRNA vaccine option, to be successful in the domestic […]
Read more

Eisai and Biogen’s lecanemab finally shows potential for targeting amyloid beta in Alzheimer’s disease, says GlobalData

Following the news that Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb) lecanemab was effective in reducing cognitive clinical decline among patients with early Alzheimer’s disease (AD) in the Phase III Clarity AD trial (NCT03887455); Pippa Salter, Senior Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “After multiple failures, […]
Read more

Sanofi and Regeneron’s positive data for Dupixent in children will help companies remain market leaders for next five to 10 years, says GlobalData

Following the news that Sanofi and Regeneron presented analyses from the LIBERTY AD PRESCHOOL (NCT03346434) study of interleukin (IL)-4/13 inhibitor, Dupixent (dupilumab), at the European Academy of Dermatology and Venereology (EADV) 2022; Ramla Salad, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Dupixent is proving to be very efficacious, even […]
Read more

Bayer chronic kidney disease medication Kerendia can gain quick market penetration in India, says GlobalData

Bayer has recently launched its first-in-class non-steroidal, selective mineralocorticoid receptor antagonist, Kerendia (finerenone), for patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in India. Considering the large diabetes patient population in the country, Kerendia can gain quick market penetration, says GlobalData, a leading data and analytics company. GlobalData’s ‘Pharmaceutical Intelligence Center’ […]
Read more

AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData

Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca‘s long-acting antibody combination “Evusheld” for the prevention (pre-exposure prophylaxis (PrEP) and treatment of COVID-19. The government’s decision to limit the drug’s supply to only COVID-19 prevention will still likely encourage its uptake, says GlobalData, a leading data and analytics company. According to GlobalData’s […]
Read more

Inflation, geopolitical events continue to challenge post-COVID-19 recovery of healthcare systems, observes GlobalData

Increasing inflation and the cost of living crisis, fueled by the COVID-19 pandemic and geopolitical events such as the ongoing Ukraine conflict, continue to challenge the pharmaceutical supply chains and the healthcare revenue cycle, observes GlobalData, a leading data and analytics company. A poll by GlobalData found that 31% of people believe that supply chains […]
Read more

Neither Convidecia Air nor BBV154 are first inhaled COVID-19 vaccines to be approved, but this category could be key to breaking COVID-19 wave cycle, says GlobalData

Contrary to some media claims, neither CanSino Biologics’ Convidecia Air nor Bharat Biotech’s BBV154 are the first inhaled COVID-19 vaccines to market, according to GlobalData, which highlights that two such vaccines were approved in Russia in March and July this year. However, the leading data and analytics company notes that the trend towards inhaled vaccines […]
Read more

13 of top 20 biopharmaceutical companies by revenue reported more than 10% YoY revenue growth from 2020 to 2021, finds GlobalData

Last year was a positive year for biopharmaceutical companies, particularly those with COVID-19 vaccines. The majority of the top 20 innovative biopharmaceutical companies reported an increase in their revenue in 2021, with an aggregate revenue of $846.8 billion and a growth of $166.4 billion over 2020, according to GlobalData, a leading data and analytics company. […]
Read more

FDA’s approval of Omicron-specific boosters is ground-breaking news but booster uptake remains poor, says GlobalData

Following the news that the FDA has approved both the Pfizer/BioNTech and the Moderna omicron-specific booster; Emily Martyn, MPH, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “The success of the mRNA* vaccine platform cannot be understated. It has saved millions of lives during the COVID-19 pandemic and revolutionized the […]
Read more

Advanced biologic drugs and COVID-19 vaccines creating opportunities for packaging providers to supply big pharma companies, says GlobalData

Injectable drugs and their packaging requirements are providing ample opportunities for packaging firms to supply big pharmaceutical companies, given the volume of vaccines, including the latest Omicron boosters required to tackle the COVID-19 pandemic, and the rising number of biologics, says GlobalData, a leading data and analytics company. GlobalData’s report, ‘Contract Injectable Packaging Trends in […]
Read more

China firms to give stiff competition to foreign counterparts in domestic HER2-/HR+ breast cancer market, says GlobalData

Human epidermal growth factor receptor 2-negative/hormone receptor-positive breast cancer (HER2-/HR+ BC) is one of the most prevalent subtypes of BC in China. Historically, foreign companies have dominated the HER2-/HR+ marketed drug space in the country. However, the trend is expected to change gradually, considering the strong innovative late stage (Phase III and above) pipeline by […]
Read more

Black participants represented only 3% of cancer clinical trial participants between 2013 and 2022, finds GlobalData

Diversity within pharmaceutical studies continues to be a problem across a wide variety of clinical trial sectors, with industry sponsors and pivotal studies particularly experiencing issues, says GlobalData. When looking specifically at oncology, the leading data and analytics company found that Black participants are severely underrepresented in these studies, only accounting for 3% of the […]
Read more

Pfizer’s discontinuation of emprumapimod following Phase III trial leaves an unmet need that pharmaceutical companies should aim to fill, says GlobalData

Based on an interim futility analysis of its global Phase III trial, REALM-DCM, Pfizer has ceased clinical trial development of its therapy emprumapimod. The drug was meant to target dilated cardiomyopathy (DCM)* patients whose condition was due to a lamin gene mutation**. According to GlobalData’s report, ‘Cardiomyopathies – Global Drug Forecast and Market Analysis to […]
Read more
1 … 44 45 46 47 48 … 110